Bosutinib: a new, safer TKI for frontline CML VJHemOnc – Video Journal of Hematology & HemOnc 1:03 6 years ago 975 Скачать Далее
5-year update of BFORE: bosutinib vs imatinib in CML VJHemOnc – Video Journal of Hematology & HemOnc 2:12 1 year ago 403 Скачать Далее
Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study VJHemOnc – Video Journal of Hematology & HemOnc 1:46 3 months ago 198 Скачать Далее
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML VJHemOnc – Video Journal of Hematology & HemOnc 1:10 1 year ago 161 Скачать Далее
Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia Targeted Oncology 0:52 5 years ago 190 Скачать Далее
Five-year follow-up data from the BFORE trial: bosutinib versus imatinib in CML VJHemOnc – Video Journal of Hematology & HemOnc 1:54 1 year ago 230 Скачать Далее
Benefits of second generation TKIs for CML in the frontline VJHemOnc – Video Journal of Hematology & HemOnc 1:46 5 years ago 73 Скачать Далее
The efficacy of nilotinib treatment approaches in frontline CML VJHemOnc – Video Journal of Hematology & HemOnc 1:26 2 years ago 753 Скачать Далее
The BYOND trial: bosutinib shows promise in heavily pre-treated CML patients VJHemOnc – Video Journal of Hematology & HemOnc 2:04 3 years ago 239 Скачать Далее
Comparing Frontline Therapies for the Treatment of Chronic Myeloid Leukemia Targeted Oncology 1:59 4 years ago 201 Скачать Далее
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid le... ecancer 4:36 2 years ago 565 Скачать Далее
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML VJHemOnc – Video Journal of Hematology & HemOnc 1:10 1 year ago 325 Скачать Далее
Fourth generation TKIs for CML: asciminib VJHemOnc – Video Journal of Hematology & HemOnc 1:32 5 years ago 1 196 Скачать Далее
Dr. Hagop Kantarjian on the Optimal Frontline Treatment for CML OncLive 0:59 11 years ago 1 135 Скачать Далее
Considerations for TKI choice in frontline and R/R CML VJHemOnc – Video Journal of Hematology & HemOnc 1:24 1 year ago 42 Скачать Далее
Managing cardiovascular risks associated with lifelong TKI therapy in CML VJHemOnc – Video Journal of Hematology & HemOnc 1:42 1 year ago 118 Скачать Далее
Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization VJHemOnc – Video Journal of Hematology & HemOnc 2:32 2 years ago 253 Скачать Далее
